Cipla Secures Exclusive Rights to HER2 Bispecific ADC TQB2102 Across Seven Emerging Markets
核心洞察
Cipla has entered an exclusive licensing and supply agreement with Sino Biopharmaceutical's subsidiary Chia Tai Tianqing (CTTQ) for the HER2 (搜索) bispecific antibody-drug conjugate TQB2102 (Rolditamig Deuderuxtecan (搜索)).
The deal grants Cipla exclusive development and commercialization rights across India, South Africa, and five other emerging markets, while CTTQ retains manufacturing and supply responsibilities.
TQB2102 has shown encouraging clinical potential in HER2 (搜索)-low advanced breast cancer (搜索) and has secured three Breakthrough Therapy Designations from China's National Medical Products Administration.
Cipla Limited has entered into an exclusive licensing and supply agreement with Chia Tai Tianqing Pharmaceutical Group (搜索) (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (SBP Group), for the potential best-in-class oncology therapy Rolditamig Deuderuxtecan (搜索) (TQB2102). The agreement grants Cipla exclusive development and commercialization rights across India, South Africa, and five other emerging markets, positioning the company to bring a next-generation HER2 (搜索)-targeted therapy to patients in these regions.
TQB2102 is a HER2 (搜索) bispecific antibody-drug conjugate (ADC) being evaluated for the treatment of HER2-expressing cancers. As a bispecific ADC, it is engineered to bind to two sites on the HER2 protein, a protein that can help drive the growth of certain cancer cells, potentially helping it target cancer cells more effectively. The drug has shown encouraging clinical potential in patients with HER2-low advanced breast cancer (搜索), and has demonstrated therapeutic potential in breast, colorectal, and biliary tract cancers.
The compound has already secured three Breakthrough Therapy Designations from China's National Medical Products Administration Centre for Drug Evaluation, underscoring its clinical significance as a late-stage, differentiated oncology asset.
Division of Responsibilities
Under the terms of the agreement, Cipla will handle local clinical development, regulatory approvals, and commercialization across the seven licensed markets. CTTQ will continue to manufacture and supply the drug, retaining all manufacturing and supply responsibilities. The companies did not disclose the financial terms of the agreement.
Cipla Managing Director and Global CEO Achin Gupta said the agreement strengthens the company's oncology portfolio with a promising HER2 (搜索)-targeted ADC and could help accelerate development and patient access, subject to regulatory approvals.
"Expanding global access to medicines developed by SBP Group is a central part of our strategy," said Sino Biopharmaceutical Group CEO Eric Tse.
Strategic Rationale
The partnership allows Cipla to add a late-stage oncology asset without requiring it to develop the molecule from scratch, bypassing early-stage drug discovery risks while leveraging its robust clinical development and marketing infrastructure across emerging markets. The treatment remains under clinical evaluation, meaning its eventual availability in Cipla's licensed markets will depend on further development and regulatory approvals.
The oncology space, particularly antibody-drug conjugates, is one of the fastest-growing segments in the global pharmaceutical industry. Bispecific ADCs like TQB2102, which bind simultaneously to multiple cancer receptor domains, represent the next frontier in targeted cancer therapy, offering higher efficacy with potentially fewer side effects. Large Indian pharmaceutical companies are increasingly relying on licensing deals to bring these advanced therapies to emerging markets.
Financial Context
Cipla's Q1 FY27 consolidated net profit fell 39.2% year-on-year to ₹789.05 crore, while revenue from operations increased 2.3% year-on-year to ₹7,119.28 crore, reflecting stable core operations. Cipla shares closed 0.89% lower at ₹1,410.80 on the NSE on Monday, August 31.
Risks and Considerations
Several risks accompany the partnership. Clinical trial risks include potential failure or delays in local clinical development and regulatory approvals for TQB2102. Regulatory scrutiny remains a concern, as evidenced by seven recent USFDA observations at Cipla's Pithampur facility. Competition from other major pharmaceutical players launching competing HER2 (搜索)-targeted therapies in the same markets also presents a challenge.
In related developments, on August 28, 2026, Cipla's US subsidiary InvaGen Pharmaceuticals received a Voluntary Action Indicated (VAI) classification from the USFDA for its New York Unit 3 facility, closing the review of its July 2026 inspection. Separately, on August 27, 2026, Cipla's joint venture Aspergen Limited, India acquired a 100% stake in Aspergen Inc., USA. However, on the same date, Cipla also received seven USFDA observations in Form 483 for its Pithampur facility.